

RIBOSOMAL P ANTIGEN

AROTEC_RiboP_Product_Info.pdf Version/Date: B/04.05.25

ATR03-02	Ribosomal P antigen	0.20 mg
ATR03-05	Ribosomal P antigen	0.50 mg
ATR03-10	Ribosomal P antigen	1.0 mg

Description of the Product

Purified from bovine thymus. After coating onto ELISA plates the product will bind autoantibodies to ribosomal P antigen.

Purity: The ribosomal P antigen subunits P0, P1 and P2 (38, 19 and 17 kDa respectively) are more than 90% pure, as assessed by SDS-polyacrylamide gel electrophoresis.

Concentration: 0.1-1.0 mg protein/ml.

Storage: The product is stabilised with 20% glycerol and 0.1% Micr-O-protect™. Store at -20 °C or below (long term) or at +4°C (short term). Avoid repeated freezing and thawing. Mix thoroughly before use.

Clinical and Biochemical Data

The existence of autoantibodies to ribosomal components has been known for some time^{1,2}. In 1985, two groups independently identified the ribosomal P proteins as the major protein antigens recognised by ribosomal antibodies^{3,4}. Anti-ribosomal P antibodies are considered to be very specific for systemic lupus erythematosus (SLE)^{5,6}, and their presence frequently correlates with disease activity, in particular psychotic depression⁶, hepatitis⁷⁻⁹, and nephritis^{10,11}. Although anti-ribosomal P antibodies have been reported to occur in patients with systemic sclerosis¹², this would appear to be rare and normally indicates an overlap with SLE¹³.

The P proteins are three of approximately 80 proteins that make up the largest cytoplasmic ribonucleoprotein, the ribosome. Since ribosomes are assembled in the nucleoli, high titre anti-ribosomal P sera will show nucleolar as well as cytoplasmic immunofluorescent staining¹⁴. The exact functions of the individual P proteins are not fully understood however studies suggest that they collectively comprise part of a functional GTPase domain necessary for the binding of factor-GTP complexes^{15,16}. This interaction results in catalysis of the appropriate step of the protein synthesis cycle (initiation, elongation or release). GTP is hydrolysed and the factor is released. The ribosomal P proteins are distinctive through their overall net negative charge, high content of alanine and predicted secondary structure (approx. 70% helical)¹⁴. The C-terminal 17 amino acids of all three P proteins are virtually identical and are highly conserved between species. Although the major autoantibody epitope on all three proteins is believed to be located within the C-terminal 22 amino acids^{14,17}, there is recent evidence that other individual P protein-specific epitopes occur¹⁸.

The ribosomal P0, P1 and P2 proteins are all present in AroTec's ribosomal P antigen. The antigen typically exhibits a 260/280 nm absorbance ratio of >1.5, suggesting that a significant rRNA component is present. The sequences of the bovine P0 and P2 proteins have been determined¹⁹, and found to be very homologous (>99%) to their human equivalents²⁰. In particular the C-terminal 22 amino acids of both species were found to be identical.

Methodology

The following is an ELISA procedure which can be used to detect anti-ribosomal P autoantibodies in human serum using the ATR03 purified autoantigen:

1. Dilute the purified antigen to 0.5-1.0 µg/ml in PBS (10 mM potassium phosphate, pH 7.4, 0.15 M NaCl).
2. Coat ELISA plates with 100 µl of diluted antigen per well. Cover and incubate 24 hours at +4°C.
3. Empty the plates and remove excess liquid by tapping on a paper towel.
4. Block excess protein binding sites by adding 200 µl PBS containing 1% BSA per well. Cover and incubate at +4°C overnight.
5. Empty plates and apply 100 µl of serum samples diluted 1:100 in PBS / 1% BSA / 1% casein / 0.1% Tween® 20. Incubate at room temperature for 1 hour.
6. Empty plates and add 200 µl PBS / 0.1% Tween® 20 per well. Incubate 5 minutes then empty plates. Repeat this step twice.
7. Apply 100 µl anti-human IgG-enzyme conjugate (horseradish peroxidase or alkaline phosphatase) diluted in PBS / 1% BSA / 1% casein / 0.1% Tween® 20 per well and incubate for 1 hour.
8. Repeat step 6.
9. Add enzyme substrate and stop the reaction when appropriate.
10. Read absorbance in an ELISA spectrophotometer.

References

1. Sturgill, P.H. et al. (1965) *Arthritis Rheum.* **8**, 213
2. Schur, P.H. et al. (1967) *Immunochemistry* **4**, 447
3. Elkon, K.B. et al. (1985) *J. Exp. Med.* **162**, 459
4. Francoeur, A.-M. et al. (1985) *J. Immunol.* **135**, 2378
5. Elkon, K.B. et al. (1992) *Rheum. Dis. Clin.* **18**, 377
6. Teh, L.S. & Isenberg, D.A. (1994) *Arthritis Rheum.* **37**, 307
7. Koren, E. et al. (1993) *Arthritis Rheum.* **36**, 1325
8. Hulseley, M. et al. (1995) *Clin. Immunol. Immunopathol.* **74**, 252
9. Arnett, F.C. & Reichlin, M. (1995), *Am. J. Med.* **99**, 465
10. Martin, A.L. & Reichlin, M. (1996) *Lupus* **5**, 22
11. Sato, T. et al. (1991) *J. Rheumatol.* **18**, 1681
12. Fujimoto, M. et al. (1996) *J. Dermatol.* **23**, 33
13. Fujimoto, M. et al. (1995) *Br. J. Rheumatol.* **34**, 908
14. Elkon, K.B. (1994) *Man. Biol. Markers Dis. (Kluwer Acad. Publ.)* **B2.5/1-11**
15. Chu, J.L. et al. (1991) *J. Exp. Med.* **174**, 507
16. Teh, L.S. et al. (1992) *Br. J. Rheumatol.* **32**, 287
17. Elkon, K. et al. (1986) *Proc. Natl. Acad. Sci. USA* **83**, 7419
18. Fabien, N. et al. (1999) *J. Autoimmun.* **13**, 103
19. SWISS-PROT RLA0_BOVIN primary accession number Q95140 & RLA2_BOVIN primary accession number P42899
20. Rich, B.E. & Steitz, J.A. (1987) *Mol. Cell Biol.* **7**, 4065

Micr-O-protect is from Roche Diagnostics GmbH (Mannheim, Germany).
Tween® 20 is a registered trademark of ICI Americas Inc.

NOTE: **No patented technology** has been used by AroTec during the preparation of this product.



AROTEC DIAGNOSTICS LIMITED